The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
The results of a follow-up analysis to the phase III  MAVORIC study were presented at the ASH 2018 Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Traci DeVito Source Type: news

What Causes Post-Inflammatory Hypopigmentation?
Discussion Hypopigmentation can be worrisome for many families because of cosmesis and the worry that “something is wrong.” The normal natural changes in skin-tone over the year due to different light exposure and wide variations within individuals is not something that many people are aware of. Post-inflammatory hypopigmentation is a common cause of hypopigmentation. Vitiligo is the most common cause of depigmentation. Vitiligo is an acquired, depigmenting disorder with typical lesions appearing as milky white macules with distinct margins that are not scaly. Hair (including eyebrows and eyelashes) can be dep...
Source: PediatricEducation.org - November 12, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Oct. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where t... Biopharmaceuticals, Oncology Soligenix, hypericin, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 15, 2018 Category: Pharmaceuticals Source Type: news

Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for  relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and S ézary Syndrome
August 8, 2018 -- The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S ézary syndrome (SS) after... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 8, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Drug for Cutaneous T-Cell Lymphomas FDA Approves New Drug for Cutaneous T-Cell Lymphomas
The FDA has granted approval for mogamulizumab-kpkc for adult patients with relapsed or refractory mycosis fungoides or S é zary syndrome.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or S ézary syndrome after at least one prior systemic therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 8, 2018 Category: American Health Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Mycosis Fungoides and Sezary Syndrome
Mycosis Fungoides and S é zary Syndrome (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 16, 2018 Category: General Medicine Source Type: news

Proposed Remetinostat Phase III Design Results in Delay in Planned Start of Study
STOCKHOLM, June 18, 2018 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Board of Directors have decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the d... Biopharmaceuticals, Oncology Medivir, remetinostat, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 18, 2018 Category: Pharmaceuticals Source Type: news

New tool predicts deadly form of rare cancer
(Brigham and Women's Hospital) A tool to accurately determine which early-stage patients are at risk of dying from mycosis fungoides and which patients are likely to only require conventional therapy is desperately needed. Investigators from Brigham and Women's Hospital have found that next-generation, high-throughput sequencing of a specific gene (T-cell receptor beta or TCRB) is a stronger predictor of which early-stage patients will develop aggressive, progressive MF than any other established factor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news

New Tool Predicts Deadly Form of Rare Cancer
Genetic sequencing from biopsy can accurately predict which early-stage Cutaneous T Cell Lymphoma (CTCL) patients have aggressive form of this disease (Source: BWH News)
Source: BWH News - May 9, 2018 Category: Hospital Management Source Type: news

Kim Debling shares photos of incurable cancer's disfiguring effects
Kim Debling, 34, from Basingstoke, Hampshire, is virtually unrecognisable after red lumps ravaged her face - caused by her stage four Cutaneous T-Cell lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2018 Category: Consumer Health News Source Type: news

Mother-of-two, 34, with an incurable cancer releases shocking photos of its disfiguring effects
Kim Debling, 34, from Basingstoke, Hampshire, is virtually unrecognisable after red lumps ravaged her face - caused by her stage four Cutaneous T-Cell lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2018 Category: Consumer Health News Source Type: news

Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S ézary Syndrome
A Guide for the Practicing OncologistThird Edition CLICK HERE TO ACCESS THE WHITE PAPER (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Tags: Sponsored Resources Source Type: news

Mogamulizumab: Valuable New Option for Cutaneous Lymphoma Mogamulizumab: Valuable New Option for Cutaneous Lymphoma
An investigational monoclonal antibody directed against chemokine receptor 4 significantly improved progression-free survival in patients with cutaneous T-cell lymphoma.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma FDA Approves Brentuximab for Cutaneous T-Cell Lymphoma
The drug had significant advantages over two other currently used agents in a phase 3 clinical trial.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Seattle Genetics Announces FDA Approval of Adcetris (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 9, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2017 Category: Drugs & Pharmacology Source Type: news

EC grants marketing authorisation for Actelion ’s Ledaga to treat MF-CTCL
The European Commission (EC) has granted marketing authorisation for 160mcg of Actelion ’s Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news

Trillium begins dosing in Phase I trial of TTI-621 for solid tumours and mycosis fungoides
Clinical stage immuno-oncology company Trillium Therapeutics has begun dosing in its second Phase I clinical trial of TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously accessible solid tumours and mycosis fungoides. (Source: Drug Development Technology)
Source: Drug Development Technology - February 1, 2017 Category: Pharmaceuticals Source Type: news

Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma Superior Outcomes With Brentuximab in Cutaneous T Cell Lymphoma
Brentuximab vedotin showed clinically superior outcomes compared with standard of care in patients with cutaneous T cell lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Angimmune ’s Investigational Cutaneous T-cell Lymphoma Disease...
FDA Fast Track Granted to Angimmune(PRWeb September 13, 2016)Read the full story at http://www.prweb.com/releases/angimmune/201609/prweb13679453.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 13, 2016 Category: Pharmaceuticals Source Type: news

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administrat... Biopharmaceuticals, Oncology, FDA Trillium Therapeutics, SIRPaFc, TTI-621, mycosis fungoides (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 17, 2016 Category: Pharmaceuticals Source Type: news

Takeda and Seattle Genetics report positive results from Phase III ALCANZA trial of Adcetris to treat CTCL
Takeda Pharmaceutical and Seattle Genetics have reported positive results from the Phase III ALCANZA clinical trial of Adcetris to treat cutaneous T-cell lymphoma (CTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - August 1, 2016 Category: Pharmaceuticals Source Type: news

Severe psoriasis upped lymphoma risk in large cohort study
SCOTTSDALE, ARIZ. – Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5 times, in a large, longitudinal, population-based cohort study. Psoriasis also was tied to a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 6, 2016 Category: Dermatology Source Type: news

Severe psoriasis upped lymphoma risk in large cohort study
SCOTTSDALE, ARIZ. – Psoriasis of all severities was linked to a 3.5-fold increase in risk of cutaneous T-cell lymphoma, and severe psoriasis upped the associated risk of Hodgkin lymphoma by about 2.5... (Source: Family Practice News)
Source: Family Practice News - July 6, 2016 Category: Primary Care Source Type: news

Cutaneous T-Cell Lymphoma: Focus on Targeted AgentsCutaneous T-Cell Lymphoma: Focus on Targeted Agents
This review explores the latest targeted therapies which provide treatment options for patients with advanced cutaneous T-cell lymphoma. Which are currently approved and which are under investigation? American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2016 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma
Patients with cutaneous T-cell lymphoma who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news

Dose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell LymphomaDose-Sparing Romidepsin Regimens Promising in Cutaneous T-Cell Lymphoma
Romidepsin regimens that employ less-frequent dosing can prolong remission in patients with some subtypes of cutaneous T-cell lymphoma (CTCL), according to a retrospective records review. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

APO866 lacks efficacy in cutaneous T-cell lymphoma
The nicotinamide adenine dinucleotide biosynthesis inhibitor APO866 does not show efficacy in patients with cutaneous T-cell lymphoma, according to phase II trial results reported in JAMA Dermatology. (Source: MedWire News)
Source: MedWire News - April 7, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news

miRagen begins Phase I trial for MRG-106 to treat cutaneous T-cell lymphoma
US-based miRagen Therapeutics has started a Phase I trial of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, to treat patients with lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 3, 2016 Category: Pharmaceuticals Source Type: news

Mycosis Fungoides: A Type of Skin Cancer
General information regarding Mycosis Fungoides including stages and current treatment options (Source: Disabled World)
Source: Disabled World - February 5, 2016 Category: Disability Tags: Skin Cancer & Melanoma Source Type: news

Topical resiquimod effective for early-stage cutaneous T-cell lymphoma
Topical resiquimod was effective and well tolerated in patients with early-stage cutaneous T-cell lymphoma (CTCL), in some cases inducing regression in both treated and untreated lesions, according to researchers. The mean number of prior unsuccessful therapies among the patients was 6, yet the... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 24, 2015 Category: Dermatology Source Type: news

Medical News Today: Topical drug leads to complete remission for some patients with rare skin lymphoma
Researchers reveal how a topical drug called resiquimod led to total remission for some patients with a cutaneous T cell lymphoma - a rare skin lymphoma. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 7, 2015 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Topical gel proves safe, effective treatment for patients with skin t cell lymphoma
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma that affects the skin. Currently, there is no cure for CTCL aside from a bone marrow transplant. However, the new study shows that the topical gel can eliminate malignant T cells, leading to diminished lesions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 6, 2015 Category: Science Source Type: news

Naloxone lotion improves disabling itch in CTCL
VANCOUVER, B.C. – Naloxone lotion appears to be a safe and effective treatment for the severe chronic itching that occurs in most patients with cutaneous T-cell lymphoma, Dr. Madeleine Duvic reported at the World Congress of Dermatology. A major unmet need exists for better treatments for...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 2, 2015 Category: Dermatology Source Type: news

Your NEJM Group Today: Cutaneous T-Cell Lymphoma, Sunscreen Use, Washington State IM Opportunity (FREE)
By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 23, 2015 Category: Primary Care Source Type: news

Check sweat glands, hair follicles in mycosis fungoides
SAN FRANCISCO – Check for syringotropism and folliculotropism in biopsies when managing mycosis fungoides, based on data from an ongoing observational, prospective study at Thomas Jefferson University in Philadelphia. The presence of syringotropism and folliculotropism indicates the need for more... (Source: Skin and Allergy News)
Source: Skin and Allergy News - April 22, 2015 Category: Dermatology Tags: SAN Conference News SAN Clinical News SAN News American Academy of Dermatology Source Type: news

Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market...
RnRMarketResearch.com adds “Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015” to its store. The report provides an overview of the Cutaneous T-Cell Lymphoma’s therapeutic pipeline.(PRWeb April 07, 2015)Read the full story at http://www.prweb.com/releases/cutaneous-t-cell-lymphoma/pipeline-review-h1-2015/prweb12636381.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 7, 2015 Category: Pharmaceuticals Source Type: news

FDA Approves Poteligeo for Rare Types of Non - Hodgkin Lymphoma
Drug approved to treat relapsed or refractory mycosis fungoides and Sézary syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

Mycosis Fungoides and Leiomyosarcoma – Cancer Therapeutic Drugs and...
RnRMarketResearch.com adds “Mycosis Fungoides and Leiomyosarcoma – Pipeline Review, H2 2014” to its store. The report provides an overview of the Mycosis Fungoides and Leiomyosarcoma therapeutic...(PRWeb October 31, 2014)Read the full story at http://www.prweb.com/releases/2014-h2-retinoblastoma/leiomyosarcoma-pipeline/prweb12293087.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 1, 2014 Category: Pharmaceuticals Source Type: news

Response to Alemtuzumab for Leukemic Cutaneous T-Cell LymphomaResponse to Alemtuzumab for Leukemic Cutaneous T-Cell Lymphoma
Patients with leukemic cutaneous T-cell lymphoma (CTCL) who have diffuse erythema are more likely to experience complete response to alemtuzumab therapy, according to results from a small series. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 2, 2014 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Novel Drug Shows Promise in T-Cell Lymphoma
DENVER (MedPage Today) -- An investigational drug, resiquimod, successfully healed cutaneous T-cell lymphoma lesions in a small peer-supported trial, researchers reported here. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 24, 2014 Category: Dermatology Source Type: news

Should You Use Your Hand to Score Skin in CTCL?Should You Use Your Hand to Score Skin in CTCL?
Learn about a new iPhone app that can help with BSA assessment in CTCL. The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2013 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

First Proprietary Gel Product for Cutaneous Lymphoma First Proprietary Gel Product for Cutaneous Lymphoma
Although topical mechlorethamine (nitrogen mustard) has been used for decades in cutaneous T-cell lymphoma, only now is the product launched. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
WOODCLIFF LAKE, N.J., Aug. 8, 2013 -- (Healthcare Sales & Marketing Network) -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell ly... Biopharmaceuticals, Oncology, FDAEisai, orphan drug, E7777, cutaneous t-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 8, 2013 Category: Pharmaceuticals Source Type: news

Skin Infections With Electron Beam Therapy for Mycosis...Skin Infections With Electron Beam Therapy for Mycosis...
There is a significant risk of cutaneous infection during total skin electron beam therapy (TSEBT) for mycosis fungoides, according to a new case series. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2013 Category: Consumer Health News Tags: Dermatology News Source Type: news

Non-mycosis Fungoides Cutaneous T-cell LymphomasNon-mycosis Fungoides Cutaneous T-cell Lymphomas
Primary cutaneous CD30+ T-cell lymphoproliferative disorders and their differential diagnosis are highlighted in this report from the European Society for Hematopathology. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Anti-Cancer Drug Reverses Alzheimer's Disease In Mice
An anti-cancer drug may reverse memory problems in an Alzheimer's Disease mouse model, according to new research carried out at the University of Pittsburgh Graduate School of Public Health. The study, published in the journal Science, examined previously published outcomes on the drug bexarotene - which is approved by the U.S. Food and Drug Administration for use in cutaneous T cell lymphoma... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 25, 2013 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news

Mycosis Fungoides and Sézary Syndrome
The development of array comparative genomic hybridization (aCGH) techniques has allowed to characterize more precisely several human neoplasms with the aim of providing prognostic markers and targets for directed therapeutic intervention. Recently, several studies applying aCGH technique have been reported in which an exhaustive genetic characterization of mycosis fungoides (MF) and Sézary syndrome (SS) has been performed. Regarding MF, a genomic profile characterized by the gains of 7q, 17q, and 8q and losses in 9p, 13q, 17p, and 10q has been described. In SS, the most common abnormalities are gains in 8q and 17q ...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news